MA43053A - Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation - Google Patents
Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisationInfo
- Publication number
- MA43053A MA43053A MA043053A MA43053A MA43053A MA 43053 A MA43053 A MA 43053A MA 043053 A MA043053 A MA 043053A MA 43053 A MA43053 A MA 43053A MA 43053 A MA43053 A MA 43053A
- Authority
- MA
- Morocco
- Prior art keywords
- human
- methods
- binding specifically
- antibodies binding
- antagonist antibodies
- Prior art date
Links
- 101150013553 CD40 gene Proteins 0.000 title 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562234812P | 2015-09-30 | 2015-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA43053A true MA43053A (fr) | 2018-08-08 |
Family
ID=58409279
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043055A MA43055A (fr) | 2015-09-30 | 2016-09-30 | Anticorps agonistes se liant de manière spécifique au cd40 humain et procédés d'utilisation |
MA043053A MA43053A (fr) | 2015-09-30 | 2016-09-30 | Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA043055A MA43055A (fr) | 2015-09-30 | 2016-09-30 | Anticorps agonistes se liant de manière spécifique au cd40 humain et procédés d'utilisation |
Country Status (23)
Country | Link |
---|---|
US (2) | US20190048089A1 (fr) |
EP (2) | EP3355921A4 (fr) |
JP (2) | JP2018529351A (fr) |
KR (2) | KR20180054837A (fr) |
CN (2) | CN109069622A (fr) |
AU (2) | AU2016331819B2 (fr) |
BR (2) | BR112018006251A2 (fr) |
CA (2) | CA3000400A1 (fr) |
CL (1) | CL2018000833A1 (fr) |
CO (1) | CO2018003436A2 (fr) |
CR (1) | CR20180177A (fr) |
EA (1) | EA037882B1 (fr) |
EC (1) | ECSP18033227A (fr) |
ES (1) | ES2906823T3 (fr) |
IL (1) | IL258268B (fr) |
MA (2) | MA43055A (fr) |
MX (1) | MX2018003905A (fr) |
MY (1) | MY196646A (fr) |
NI (1) | NI201800044A (fr) |
PE (1) | PE20181367A1 (fr) |
PH (1) | PH12018500684A1 (fr) |
SV (1) | SV2018005659A (fr) |
WO (2) | WO2017059243A2 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3355921A4 (fr) * | 2015-09-30 | 2019-05-22 | Janssen Biotech, Inc. | Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation |
FI3468997T3 (fi) | 2016-06-08 | 2023-10-31 | Xencor Inc | Igg4:ään liittyvien sairauksien hoito anti-cd19-vasta-aineilla, jotka ristisitoutuvat cd32b:een |
EP3471753A1 (fr) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 et cytokines il-2 |
WO2018160917A1 (fr) * | 2017-03-03 | 2018-09-07 | Janssen Biotech, Inc. | Co-thérapie comprenant un inhibiteur de csf-1r à petite molécule et un anticorps agoniste qui se lie spécifiquement au cd40 pour le traitement du cancer |
KR20200012907A (ko) * | 2017-05-25 | 2020-02-05 | 브리스톨-마이어스 스큅 컴퍼니 | 변형된 IgG1 Fc 도메인 및 그와의 항-CD40 도메인 항체 융합체 |
KR20200011937A (ko) | 2017-05-25 | 2020-02-04 | 브리스톨-마이어스 스큅 컴퍼니 | 길항작용 cd40 모노클로날 항체 및 그의 용도 |
CN110831970A (zh) * | 2017-06-02 | 2020-02-21 | 辉瑞公司 | 靶向flt3的嵌合抗原受体 |
WO2019057792A1 (fr) | 2017-09-19 | 2019-03-28 | Mab Discovery Gmbh | Anticorps cd40 agonistes |
CN111263771A (zh) * | 2017-11-03 | 2020-06-09 | 诺华股份有限公司 | 用于治疗干燥综合征的抗cd40抗体 |
AR117091A1 (es) | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
AU2020256828A1 (en) | 2019-04-10 | 2021-11-18 | Nankai University | Anti-CD40 antibody and use thereof |
WO2021127528A1 (fr) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Constructions d'anticorps multispécifique agoniste de cd40 ciblé par la mésothéline permettant le traitement de tumeurs solides |
WO2021195326A1 (fr) * | 2020-03-26 | 2021-09-30 | Vanderbilt University | Anticorps monoclonaux humains dirigés contre le coronavirus du syndrome respiratoire aigu sévère 2 (sras-cov-2) |
WO2022002065A1 (fr) * | 2020-06-30 | 2022-01-06 | 百奥泰生物制药股份有限公司 | Anticorps anti-cd40 ou son fragment de liaison à l'antigène et utilisation associée |
US20240109973A1 (en) * | 2020-12-16 | 2024-04-04 | Memorial Sloan Kettering Cancer Center | Cd40 binding molecules and uses thereof |
BR112023026111A2 (pt) * | 2021-06-28 | 2024-03-05 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo |
WO2023009891A2 (fr) * | 2021-07-30 | 2023-02-02 | Janssen Biotech, Inc. | Matériaux et procédés de fabrication ou d'utilisation de protéines de liaison à il-23 r |
WO2023020475A1 (fr) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Anticorps ciblant cd40 et leurs utilisations |
CA3228641A1 (fr) * | 2021-08-24 | 2023-03-02 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Molecule de liaison a fap/cd40 et son utilisation medicinale |
Family Cites Families (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US226A (en) | 1837-06-03 | Samuel goss | ||
US7709A (en) | 1850-10-08 | Chas S Gaylord | Improved spring-grapple | |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5247069A (en) | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
WO1988001649A1 (fr) | 1986-09-02 | 1988-03-10 | Genex Corporation | Molecules de liaison de chaines de polypeptide simples |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
ES2273452T3 (es) * | 1992-07-09 | 2007-05-01 | Novartis Vaccines And Diagnostics, Inc. | Anticuerpos monoclonales antagonistas contra la molecula humana cd40. |
RO118524B1 (ro) | 1992-11-13 | 2003-06-30 | Idec Pharmaceuticals Corp San | Metoda pentru tratarea unei tulburari legata de celulele b |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
CA2150262C (fr) | 1992-12-04 | 2008-07-08 | Kaspar-Philipp Holliger | Proteines fixatrices multivalentes et multispecifiques, fabrication et utilisation |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
KR960704576A (ko) | 1993-10-01 | 1996-10-09 | 크리스토퍼 엘. 와이트 | CD40에 대한 항체(Antibodies to CD40) |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
US6818749B1 (en) | 1998-10-31 | 2004-11-16 | The United States Of America As Represented By The Department Of Health And Human Services | Variants of humanized anti carcinoma monoclonal antibody cc49 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
JP2003531821A (ja) | 1999-12-29 | 2003-10-28 | イムノージェン インコーポレーテッド | 改変型ドキソルビシンおよびダウノルビシンを含む細胞傷害性薬剤ならびにその治療上の使用 |
MXPA02007473A (es) | 2000-02-01 | 2003-09-22 | Tanox Inc | Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40. |
WO2001058953A2 (fr) | 2000-02-11 | 2001-08-16 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Identification d"un nouveau domaine dans la famille des recepteurs du facteur de necrose tumorale mediant l"assemblage et la fonction du recepteur de pre-ligand |
AU2001259215A1 (en) | 2000-04-28 | 2001-11-12 | La Jolla Institute For Allergy And Immunology | Human anti-cd40 antibodies and methods of making and using same |
AU2002211366A1 (en) | 2000-10-02 | 2002-04-15 | Chiron Corporation | Human anti-cd40 antibodies |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
EP2009027B1 (fr) * | 2001-04-27 | 2014-05-21 | Kyowa Hakko Kirin Co., Ltd. | Anticorps monoclonal anti-CD40 |
EP1283053A1 (fr) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibiteurs de l'activité de HER3 |
WO2003029296A1 (fr) * | 2001-10-02 | 2003-04-10 | Chiron Corporation | Anticorps humains diriges contre le cd40 |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
WO2003074679A2 (fr) | 2002-03-01 | 2003-09-12 | Xencor | Optimisation d'anticorps |
DE60312507T3 (de) | 2002-05-17 | 2011-08-18 | Alligator Bioscience Ab | Eine methode zur in vitro molekularen evolution der proteinfunktion |
IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
CN100558895C (zh) * | 2003-07-18 | 2009-11-11 | 持田制药株式会社 | 抗血小板膜糖蛋白vi单克隆抗体 |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
US20050202531A1 (en) | 2003-11-03 | 2005-09-15 | Compugen Ltd. | CD40 splice variants, compositions for making and methods of using the same |
KR101128777B1 (ko) * | 2003-11-04 | 2012-04-13 | 조마 테크놀로지 리미티드 | 다발성 골수종을 치료하기 위한 길항제 항-cd40단클론성 항체의 용도 |
SI1682180T1 (sl) | 2003-11-04 | 2010-03-31 | Novartis Vaccines & Diagnostic | Antagonist anti cd monoklonskih antiteles in postopek za njihovo uporabo |
US8277810B2 (en) * | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
KR101192496B1 (ko) | 2003-11-06 | 2012-10-18 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
PL1707627T3 (pl) * | 2003-12-25 | 2013-04-30 | Kyowa Hakko Kirin Co Ltd | Mutant antagonistycznego przeciwciała anty-CD40 |
BRPI0510317A (pt) | 2004-04-27 | 2007-10-16 | Novartis Vaccines & Diagnostic | anticorpos monoclonais anti-cd40 antagonistas e métodos para seu uso |
JP2008505174A (ja) | 2004-07-15 | 2008-02-21 | ゼンコー・インコーポレイテッド | 最適化Fc変異体 |
CA2577082A1 (fr) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Molecules heteromultimeriques |
WO2006081139A2 (fr) * | 2005-01-26 | 2006-08-03 | Abgenix, Inc. | Anticorps diriges contre interleukine-1 beta |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
PL2439273T3 (pl) | 2005-05-09 | 2019-08-30 | Ono Pharmaceutical Co., Ltd. | Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami |
KR100991010B1 (ko) * | 2005-05-26 | 2010-10-29 | 제넨테크, 인크. | 인간화 항-cd40 항체 및 그의 사용 방법 |
DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
AU2006308860B2 (en) * | 2005-11-01 | 2012-01-12 | Novartis Ag | Uses of anti-CD40 antibodies |
CA2646965C (fr) | 2006-03-24 | 2016-06-21 | Jonathan H. Davis | Domaines de proteine heterodimerique d'ingenierie |
JP5290152B2 (ja) * | 2006-04-21 | 2013-09-18 | ノバルティス アーゲー | 拮抗剤抗cd40抗体薬学的組成物 |
EP1854810A1 (fr) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12 |
CN101460519B (zh) * | 2006-06-06 | 2013-06-19 | 克鲁塞尔荷兰公司 | 具有杀灭葡萄球菌活性的人结合分子及其应用 |
EP2035456A1 (fr) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production d'anticorps bispécifiques |
US20090074711A1 (en) | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
CN102123712B (zh) * | 2006-12-13 | 2014-03-19 | 默沙东公司 | 使用igf1r抑制剂治疗癌症的方法 |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
NZ600143A (en) * | 2007-02-23 | 2013-01-25 | Baylor Res Inst | Therapeutic applications of activation of human antigen-presenting cells through dectin-1 |
CA2693053C (fr) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Procedes et compositions permettant l'inhibition de cellules d'expression du cd32b |
EP2170959B1 (fr) | 2007-06-18 | 2013-10-02 | Merck Sharp & Dohme B.V. | Anticorps dirigés contre le récepteur humain de mort programmée pd-1 |
KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | pIX又はpVIIへの融合を介したヒトデノボpIXファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
AU2009206506B2 (en) | 2008-01-23 | 2013-01-10 | Xencor, Inc. | Optimized CD40 antibodies and methods of using the same |
JP2011517662A (ja) | 2008-03-03 | 2011-06-16 | ダイアックス コーポレーション | メタロプロテアーゼ9結合タンパク質 |
US20100261620A1 (en) | 2008-10-14 | 2010-10-14 | Juan Carlos Almagro | Methods of Humanizing and Affinity-Maturing Antibodies |
DK2406289T3 (en) | 2009-03-10 | 2017-05-01 | Baylor Res Inst | ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES |
CA2759146C (fr) | 2009-04-20 | 2017-06-13 | Kyowa Hakko Kirin Co., Ltd. | Agoniste de l'anticorps anti-cd40 |
WO2010129304A2 (fr) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Procédé de fabrication de molécules hétéromultimères |
WO2011021146A1 (fr) * | 2009-08-20 | 2011-02-24 | Pfizer Inc. | Anticorps contre l'ostéopontine |
ME03447B (fr) | 2010-03-04 | 2020-01-20 | Macrogenics Inc | Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées |
EA031872B1 (ru) * | 2010-03-31 | 2019-03-29 | Бёрингер Ингельхайм Интернациональ Гмбх | Гуманизированное антитело к cd40, его применение, фармацевтическая композиция, содержащая это антитело, и выделенный полинуклеотид, кодирующий его |
JP6167040B2 (ja) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
CA3167037A1 (fr) * | 2010-12-20 | 2012-06-28 | The Rockefeller University | Modulation d'anticorps agonistes anti-tnfr |
ES2623912T3 (es) | 2010-12-23 | 2017-07-12 | Janssen Biotech, Inc. | Mutantes FC de anticuerpo activo resistente a proteasa |
US9987356B2 (en) | 2011-03-11 | 2018-06-05 | Beth Israel Deaconess Medical Center, Inc. | Anti-CD40 antibodies and methods of administering thereof |
DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
CN106928362B (zh) | 2011-04-29 | 2021-10-26 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
PE20141478A1 (es) | 2011-10-13 | 2014-10-23 | Bristol Myers Squibb Co | Polipeptidos de anticuerpos que antagonizan cd40l |
WO2013063702A1 (fr) | 2011-11-04 | 2013-05-10 | Zymeworks Inc. | Structure d'anticorps hétérodimérique stable comprenant des mutations dans le domaine fc |
JP6243345B2 (ja) * | 2011-12-05 | 2017-12-06 | ノバルティス アーゲー | 上皮細胞増殖因子受容体3(her3)に対する抗体 |
US20150037336A1 (en) * | 2012-02-22 | 2015-02-05 | U3 Pharma Gmbh | Combination of hb-egf binding protein and egfr inhibitor |
CA2867299C (fr) | 2012-03-15 | 2019-08-27 | John Chen | Anticorps anti-cd27 humains, leurs procedes et leurs utilisations |
US8781132B2 (en) * | 2012-03-19 | 2014-07-15 | Motorola Solutions, Inc. | Method and device for managing encrypted group rekeying in a radio network link layer encryption system |
EP2878166A1 (fr) | 2012-07-24 | 2015-06-03 | Telefonaktiebolaget L M Ericsson (Publ) | Appareil et procédé pour sélectionner dynamiquement une valeur de fenêtre de réponse d'accès aléatoire destinée à être utilisée avec des procédures d'accès aléatoire dans un réseau |
ES2776681T3 (es) | 2012-08-24 | 2020-07-31 | Chugai Pharmaceutical Co Ltd | Variante de la región Fc específica de FcgammaRIIb |
US9676861B2 (en) * | 2012-10-30 | 2017-06-13 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
WO2014078866A2 (fr) * | 2012-11-19 | 2014-05-22 | Xencor, Inc. | Immunoglobulines synthétiques ayant une demi-vie in vivo étendue |
PT3653049T (pt) | 2012-12-14 | 2023-11-14 | Omniab Inc | Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem |
US10329350B2 (en) * | 2012-12-26 | 2019-06-25 | Industrial Technology Research Institute | Method for producing a multivalent fab fragment with collagen-like peptide |
EP2943506B1 (fr) | 2013-01-10 | 2024-03-13 | Genmab B.V. | Variantes de la région fc d'igg1 humaine et leurs utilisations |
WO2014126254A1 (fr) * | 2013-02-18 | 2014-08-21 | 協和発酵キリン株式会社 | Vecteur d'expression de protéine de liaison à une membrane |
WO2014194302A2 (fr) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Protéines de liaison à l'antigène qui se lient à pd-1 |
GB201322583D0 (en) | 2013-12-19 | 2014-02-05 | Alligator Bioscience Ab | Antibodies |
WO2015133882A1 (fr) * | 2014-03-07 | 2015-09-11 | 사회복지법인 삼성생명공익재단 | Banque d'anticorps scfv, son procédé de préparation et procédé de criblage d'anticorps scfv l'utilisant |
EP3113796A1 (fr) * | 2014-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Procédé d'utilisation de polypeptides d'anticorps qui sont des antagonistes de cd40 pour traiter une affection intestinale inflammatoire (aii) |
WO2016028810A1 (fr) | 2014-08-18 | 2016-02-25 | Biogen Ma Inc. | Anticorps anti-cd40 et leurs utilisations |
EP3355921A4 (fr) * | 2015-09-30 | 2019-05-22 | Janssen Biotech, Inc. | Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation |
-
2016
- 2016-09-30 EP EP16852679.6A patent/EP3355921A4/fr not_active Withdrawn
- 2016-09-30 EP EP16852707.5A patent/EP3356532B1/fr active Active
- 2016-09-30 CA CA3000400A patent/CA3000400A1/fr active Pending
- 2016-09-30 CA CA3000396A patent/CA3000396A1/fr not_active Abandoned
- 2016-09-30 AU AU2016331819A patent/AU2016331819B2/en active Active
- 2016-09-30 CN CN201680070103.2A patent/CN109069622A/zh active Pending
- 2016-09-30 KR KR1020187011659A patent/KR20180054837A/ko not_active Application Discontinuation
- 2016-09-30 MA MA043055A patent/MA43055A/fr unknown
- 2016-09-30 EA EA201890834A patent/EA037882B1/ru unknown
- 2016-09-30 KR KR1020187010811A patent/KR20180053738A/ko unknown
- 2016-09-30 IL IL258268A patent/IL258268B/en unknown
- 2016-09-30 US US15/763,673 patent/US20190048089A1/en not_active Abandoned
- 2016-09-30 PE PE2018000484A patent/PE20181367A1/es unknown
- 2016-09-30 CR CR20180177A patent/CR20180177A/es unknown
- 2016-09-30 CN CN201680070053.8A patent/CN108368510B/zh active Active
- 2016-09-30 US US15/281,670 patent/US10544229B2/en active Active
- 2016-09-30 MX MX2018003905A patent/MX2018003905A/es unknown
- 2016-09-30 BR BR112018006251A patent/BR112018006251A2/pt not_active Application Discontinuation
- 2016-09-30 AU AU2016329057A patent/AU2016329057A1/en not_active Abandoned
- 2016-09-30 WO PCT/US2016/054764 patent/WO2017059243A2/fr active Application Filing
- 2016-09-30 BR BR112018006360A patent/BR112018006360A2/pt not_active Application Discontinuation
- 2016-09-30 WO PCT/US2016/054671 patent/WO2017059196A2/fr active Application Filing
- 2016-09-30 JP JP2018516413A patent/JP2018529351A/ja active Pending
- 2016-09-30 ES ES16852707T patent/ES2906823T3/es active Active
- 2016-09-30 MA MA043053A patent/MA43053A/fr unknown
- 2016-09-30 MY MYPI2018701233A patent/MY196646A/en unknown
- 2016-09-30 JP JP2018516550A patent/JP7057276B2/ja active Active
-
2018
- 2018-03-23 NI NI201800044A patent/NI201800044A/es unknown
- 2018-03-23 SV SV2018005659A patent/SV2018005659A/es unknown
- 2018-03-27 PH PH12018500684A patent/PH12018500684A1/en unknown
- 2018-03-27 CO CONC2018/0003436A patent/CO2018003436A2/es unknown
- 2018-03-29 CL CL2018000833A patent/CL2018000833A1/es unknown
- 2018-04-27 EC ECIEPI201833227A patent/ECSP18033227A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA43053A (fr) | Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation | |
MA44723A (fr) | Anticorps agonistes se liant au cd40 humain et leurs utilisations | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
FR22C1048I2 (fr) | Anticorps anti-cd3 et méthodes d'utilisation | |
MA44776A (fr) | Anticorps anti-vista humain et leur utilisation | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
FR23C1004I2 (fr) | Antagonistes du fcrn et procédés d'utilisation | |
MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
MA50359A (fr) | Anticorps anti-cd38 et procédés d'utilisation | |
FR21C1021I2 (fr) | Compositions d'arni de pcsk9 et methodes d'utilisation associees | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
MA42446A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
MA56165A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MA42979A (fr) | Anticorps anti-age et procédés d'utilisation correspondants | |
MA42447A (fr) | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation | |
MA46290A (fr) | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation | |
MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
MA41279A (fr) | Anticorps hétérodimériques se liant aux antigènes cd3 et tumoraux | |
MA46893A (fr) | Anticorps bispécifiques se liant au facteur ix de coagulation et au facteur x de coagulation | |
MA41294A (fr) | Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation |